Good Example Of Actavis To Acquire Durata Therapeutics, Inc Critical Thinking

The acquisition of Durata Therapeutics, Inc – a novel pharmaceutical company targeting on growth and commercialization of new therapeutics for infectious and acute diseases – by Actavis Plc – a leading international pharmaceutical company –seems to have raised eyebrows from every corner. This is because Actavis has lately been on the forefront of major and successful mergers and acquisitions. Its continuous plan seems to be founded on the strategic plan it has laid that seeks to enhance the long-term growth beginning 2015 and beyond. Indeed, Actavis has always been viewed as a company with enormous potential and speed geared towards the achievement of effective subsidiaries. As a matter of fact, Actavis confirmed that it expected this particular acquisition to have borne fruits by the end of the first year. This confirms the robust strategic plan the company has lain in order to boost its emerging infectious disease subsidiaries.
The strategic acquisition of Durata further confirms Actavis’ effective and efficient cost measures that it utilizes to achieve the highest value possible. Considering Durata’s financial status, most international pharmaceuticals companies would have simply ignored it. However, with their strong cost analytics, Actavis are able to invest in specific investments that complement their existing businesses. For instance, Durata is particularly innovative having introduced their lead product DALVANCE used in the treatment of infectious as well as acute illnesses. Indeed, it is the first intravenous antibiotic that has received approval for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in a two-dose schedule of 1000mg and later (after a week) by 500mg. With the addition of DALVANCE to their range of novel therapeutics, Actavis will be in such a fortunate position in offering innovative answers to doctors while offering immense value to hospitals and systems of healthcare globally.
The article further reports on Actavis’ stand and recognition of DALVANCE as a stable therapeutic asset with great potential. In fact, from the press brief that the CEO of Durata gives: he is appreciative of the move by Actavis to merge with Durata since they will be in a position to expand their reach, gain additional resources, and scale to extend their commercial potential as well as patient access. Paul R. Edick, the CEO of Durata, ascertains to the qualityandexemplary service present at Actavis that will help them shape their commercial future. Being an international company with a mandate to provide highly innovative and affordable pharmaceutical products, Actavis serves as a perfect parent for Durata Therapeutics, Inc. The success of Actavis Plc has a multi-faceted approach. First, is its organizational culture. With a robust culture, Actavis manages to strategize all its operations to run concurrently and smoothly. Secondly, a favorable external environment has been of immense support to the exponential growth of Actavis leading to the numerous mergers and acquisitions that have been observed lately. This is especially true considering its international presence and growth simultaneously. In fact, Actavis has more than 60 subsidiaries in different countries and more than 30 manufacturing and distribution bases globally. Organizational ethics is also an important factor that acts as a major contributor to Actavis’ success. Honoring their company values is important in replicating honesty even to the level of mergers and/or acquisitions. In every process and stage of their transactions, the code of ethics in the company is followed to the letter, ensuring smooth take-overs and transactions.
This analysis is totally agreeable since it is evident from the article that Actavis’ long-term growth is a wheel in motion. With well-planned strategies and plans for execution, there is no better way to define Actavis Plc than what is already said: a company in motion. The information in the analysis is indeed of relevance to future start-ups since it gives clear guidelines in exemplary business management. It is also serves as a starting point for understanding the crucial elements of success in any given company: speed, cost, innovation, quality, and service.